Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma.
Head and neck cancer
chemoradiotherapies
cisplatin
concomitant
Journal
Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
04
2021
accepted:
02
09
2021
entrez:
11
10
2021
pubmed:
12
10
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Concurrent chemoradiotherapy (CCRT) with tri-weekly high-dose cisplatin (HDC) is considered the standard regimen. However, due to significant toxicity, various weekly low-dose schedules have been increasingly used. We investigated the tolerability and survival of patients with head and neck squamous cell carcinoma (HNSCC) who underwent CCRT with low-dose weekly cisplatin (LDC) for Japanese population. A retrospective review was conducted among patients with HNSCC who were treated with CCRT/LDC in our institute. Ninety-five patients who met the criteria were enrolled in this study. We evaluated the cycle and cumulative cisplatin dose, completion rate of radiotherapy, adverse events, and survival outcome. The mean cycles and cumulative cisplatin dose were 4.7 cycles and 187 mg/m Concurrent chemoradiotherapy/LDC can be safely administered with acceptable toxicity and survival outcome even if the patients with higher age, lower eGFR, and so on.
Sections du résumé
BACKGROUND
BACKGROUND
Concurrent chemoradiotherapy (CCRT) with tri-weekly high-dose cisplatin (HDC) is considered the standard regimen. However, due to significant toxicity, various weekly low-dose schedules have been increasingly used. We investigated the tolerability and survival of patients with head and neck squamous cell carcinoma (HNSCC) who underwent CCRT with low-dose weekly cisplatin (LDC) for Japanese population.
METHODS
METHODS
A retrospective review was conducted among patients with HNSCC who were treated with CCRT/LDC in our institute. Ninety-five patients who met the criteria were enrolled in this study. We evaluated the cycle and cumulative cisplatin dose, completion rate of radiotherapy, adverse events, and survival outcome.
RESULTS
RESULTS
The mean cycles and cumulative cisplatin dose were 4.7 cycles and 187 mg/m
CONCLUSIONS
CONCLUSIONS
Concurrent chemoradiotherapy/LDC can be safely administered with acceptable toxicity and survival outcome even if the patients with higher age, lower eGFR, and so on.
Identifiants
pubmed: 34629923
doi: 10.1177/11795549211048417
pii: 10.1177_11795549211048417
pmc: PMC8493312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11795549211048417Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Jpn J Clin Oncol. 2012 Oct;42(10):927-33
pubmed: 22923484
Radiother Oncol. 2006 Apr;79(1):34-8
pubmed: 16626826
Head Neck. 2005 Jan;27(1):36-43
pubmed: 15459918
Oral Oncol. 2016 Aug;59:43-49
pubmed: 27424181
Jpn J Clin Oncol. 2014 Aug;44(8):770-4
pubmed: 24842866
Cancer Rep (Hoboken). 2021 Jun 7;:e1425
pubmed: 34101389
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Oncotarget. 2016 Oct 25;7(43):70185-70193
pubmed: 27602493
Radiat Oncol. 2019 Feb 11;14(1):32
pubmed: 30744643
J Natl Cancer Inst. 2019 May 1;111(5):490-497
pubmed: 30239887
JCI Insight. 2017 Oct 5;2(19):
pubmed: 28978800
Int Arch Otorhinolaryngol. 2017 Apr;21(2):171-177
pubmed: 28382126
J Clin Oncol. 2018 Apr 10;36(11):1064-1072
pubmed: 29220295
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Oncologist. 2017 Sep;22(9):1056-1066
pubmed: 28533474
Clin Kidney J. 2014 Apr;7(2):107-14
pubmed: 25852857
Auris Nasus Larynx. 2018 Oct;45(5):1086-1092
pubmed: 29567334
Br J Radiol. 2017 Nov;90(1079):20170442
pubmed: 29053029